Skip to main content

Peer Review reports

From: Efficacy and safety of tafolecimab in Chinese patients with heterozygous familial hypercholesterolemia: a randomized, double-blind, placebo-controlled phase 3 trial (CREDIT-2)

Original Submission
9 Oct 2022 Submitted Original manuscript
15 Oct 2022 Reviewed Reviewer Report - Zhen Zhou
23 Oct 2022 Reviewed Reviewer Report
21 Nov 2022 Reviewed Reviewer Report
6 Feb 2023 Author responded Author comments - Meng Chai
Resubmission - Version 2
6 Feb 2023 Submitted Manuscript version 2
8 Feb 2023 Reviewed Reviewer Report
11 Feb 2023 Reviewed Reviewer Report - Zhen Zhou
20 Feb 2023 Author responded Author comments - Meng Chai
Resubmission - Version 3
20 Feb 2023 Submitted Manuscript version 3
Publishing
20 Feb 2023 Editorially accepted
28 Feb 2023 Article published 10.1186/s12916-023-02797-8

You can find further information about peer review here.

Back to article page